Shares of CNS Pharmaceuticals (CNSP) are down $1.86, or 55%, to $1.52 in pre-market trading after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- Biotech Alert: Searches spiking for these stocks today
- CNS Pharmaceuticals reports cash position of $14M as of February 26
- CNS Pharmaceuticals Inc trading halted, news pending
- CNS Pharmaceuticals announces 1-for-50 reverse stock split
- CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue